Markers for efficacy of mammalian target of rapamycin inhibitor

Anticancer Research

Volumn 32, Issue 10, 2012, Pages 4235-4244

  Liao, Yu Min ^a   Sy, Alex ^b   Yen, Yun ^b,c  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Biomarker; mTOR inhibitor; Rapamycin; Review

Indexed keywords

BINDING PROTEIN; BIOLOGICAL MARKER; CETUXIMAB; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEFITINIB; GUANOSINE TRIPHOSPHATASE; INTERFERON; IRINOTECAN; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN KINASE B; PROTEIN S6; RIDAFOROLIMUS; RITUXIMAB; TEMSIROLIMUS;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER PATIENT; CANCER THERAPY; CARCINOMA; CELL GROWTH; CLINICAL TRIAL (TOPIC); COLON CANCER; DRUG EFFICACY; ENDOMETRIUM CANCER; FLUORESCENCE IN SITU HYBRIDIZATION; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; ONCOGENE K RAS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SARCOMA; SENSITIVITY ANALYSIS; SOLID TUMOR; STOMACH CANCER; VIRUS ONCOGENE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; HUMANS; MICE; NEOPLASMS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84867773481     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Gingras AC, Raught B and Sonenberg N: Regulation of translation initiation by FRAP/mTOR. Genes Dev 15: 807-826, 2001. (Pubitemid 32295062)
2. Wullschleger S, Loewith R and Hall MN: TOR signaling in growth and metabolism. Cell 124: 471-484, 2006. (Pubitemid 43199434)
3. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P and Sabatini DM: mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110: 163-175, 2002. (Pubitemid 34876545)
4. Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, Oppliger W, Jenoe P and Hall MN: Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 10: 457-468, 2002. (Pubitemid 35284167)
5. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A and Hall MN: Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6: 1122-1128, 2004. (Pubitemid 39468014)
6. Chiang GG and Abraham RT: Targeting the mTOR signaling network in cancer. Trends Mol Med 13: 433-442, 2007. (Pubitemid 47570021)
7. Meric-Bernstam F and Gonzalez-Angulo AM: Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 27: 2278-2287, 2009.
8. Wang L, Harris TE and Lawrence JC: Regulation of proline-rich AKT substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation. J Biol Chem 283: 15619-15627, 2008.
9. Wang L, Harris TE, Roth RA and Lawrence JC: PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J Biol Chem 282: 20036-20044, 2007. (Pubitemid 47100127)
10. Tee AR, Manning BD, Roux PP, Cantley LC and Blenis J: Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward RHEB. Curr Biol 13: 1259-1268, 2003. (Pubitemid 36953298)
11. Aspuria PJ and Tamanoi F: The Rheb family of GTP-binding proteins. Cell Signal 16: 1105-1112, 2004.
12. Garami A, Zwartkruis FJT, Nobukuni T, Joaquin M, Roccio M, Stocker H, Kozma SC, Hafen E, Bos JL and Thomas G: Insulin activation of RHEB, a mediator of mTOR/S6K/4E-BP signaling, Is inhibited by TSC1 and 2. Mol Cell 11: 1457-1466, 2003. (Pubitemid 36776533)
13. Roux PP, Ballif BA, Anjum R, Gygi SP and Blenis J: Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci USA 101: 13489-13494, 2004. (Pubitemid 39238430)
14. Ma L, Chen Z, Erdjument-Bromage H, Tempst P and Pandolfi PP: Phosphorylation and functional inactivation of TSC2 by Erk: Implications for tuberous sclerosisand cancer pathogenesis. Cell 121: 179-193, 2005. (Pubitemid 40546387)
15. Carriere A, Romeo Y, Acosta-Jaquez HA, Moreau J, Bonneil E, Thibault P, Fingar DC and Roux PP: ERK1/2 phosphorylate raptor to promote RAS-dependent activation of mTOR complex 1 (mTORC1). J Biol Chem 286: 567-577, 2011.
16. Hara K, Maruki Y, Long X, Yoshino K-i, Oshiro N, Hidayat S, Tokunaga C, Avruch J and Yonezawa K: Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110: 177-189, 2002. (Pubitemid 34876546)
17. Inoki K, Zhu T and Guan K-L: TSC2 mediates cellular energy response to control cell growth and survival. Cell 115: 577-590, 2003. (Pubitemid 37506046)
18. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA and Cantley LC: The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 101: 3329-3335, 2004. (Pubitemid 38338195)
19. Budanov AV and Karin M: p53 Target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 134: 451-460, 2008.
20. Schneider A, Younis RH and Gutkind JS: Hypoxia-induced energy stress inhibits the mTOR pathway by activating an AMPK/REDD1 signaling axis in head and neck squamous cell carcinoma. Neoplasia 10: 1295-1302, 2008.
21. Jefferies HBJ, Fumagalli S, Dennis PB, Reinhard C, Pearson RB and Thomas G: Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. EMBO J 16: 3693-3704, 1997. (Pubitemid 27250062)
22. Hay N and Sonenberg N: Upstream and downstream of mTOR. Genes Dev 18: 1926-1945, 2004. (Pubitemid 39071573)
23. Gingras AC, Kennedy SG, O'Leary MA, Sonenberg N and Hay N: 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the AKT(PKB) signaling pathway. Genes Dev 12: 502-513, 1998. (Pubitemid 28101013)
24. Jones RM, Branda J, Johnston KA, Polymenis M, Gadd M, Rustgi A, Callanan L and Schmidt EV: An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc. Mol Cell Biol 16: 4754-4764, 1996. (Pubitemid 26272129)
25. Schmelzle T and Hall MN: TOR, a central controller of cell growth. Cell 103: 253-262, 2000.
26. Huang CH, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu VE, Kinzler KW, Vogelstein B, Gabelli SB and Amzel LM: The structure of a human p110α/p85α complex elucidates the effects of oncogenic PI3Kα mutations. Science 318: 1744-1748, 2007. (Pubitemid 350274378)
27. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM and Moasser MM: Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445: 437-441, 2007. (Pubitemid 46160912)
28. Zheng B, Jeong JH, Asara JM, Yuan Y-Y, Granter SR, Chin L and Cantley LC: Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell 33: 237-247, 2009.
29. s6K pathway in human pancreatic cancer cells. Cancer Res 59: 3581-3587, 1999.
30. Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu J-h, Sawyers CL and Lichtenstein AK: AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-Myc Expression. J Biol Chem 279: 2737-2746, 2004. (Pubitemid 38114263)
31. Dilling MB, Germain GS, Dudkin L, Jayaraman AL, Zhang X, Harwood FC and Houghton PJ: 4E-Binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J Biol Chem 277: 13907-13917, 2002. (Pubitemid 34967997)
32. Klos KS, Wyszomierski SL, Sun M, Tan M, Zhou X, Li P, Yang W, Yin G, Hittelman WN and Yu D: ERBB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res 66: 2028-2037, 2006.
33. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW and Semenza GL: Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res 60: 1541-1545, 2000. (Pubitemid 30183422)
34. 1-arresting rapamycin-receptor complex. Nature 369: 756-758, 1994.
35. Edinger AL, Linardic CM, Chiang GG, Thompson CB and Abraham RT: Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Cancer Res 63: 8451-8460, 2003. (Pubitemid 37549501)
36. Zeng Z, Sarbassov DD, Samudio IJ, Yee KWL, Munsell MF, Ellen Jackson C, Giles FJ, Sabatini DM, Andreeff M and Konopleva M: Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 109: 3509-3512, 2007. (Pubitemid 46572543)
37. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J and Rosen N: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates AKT. Cancer Res 66: 1500-1508, 2006. (Pubitemid 43259931)
38. Wander SA, Hennessy BT and Slingerland JM: Next-generation mTOR inhibitors in clinical oncology: How pathway complexity informs therapeutic strategy. J Clin Invest 121: 1231-1241, 2011.
39. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi In, Kovacevic Z, Lesovoy V, Schmidt-Wolf IGH, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L and Motzer RJ: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281, 2007.
40. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grnüwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D and Ravaud A: Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449-456, 2008.
41. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EGE, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D and Öberg K: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364: 514-523, 2011.
42. Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, Pritchard K, Eisen A, Vandenberg T, Taylor M, Sauerbrei E, Mishaeli M, Huntsman D, Walsh W, Olivo M, McIntosh L and Seymour L: Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC clinical Trials Group IND.163. J Clin Oncol 27: 4536-4541, 2009.
43. Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, Eiermann W, Hess D, Morant R, Semiglazov V, Borner M, Salzberg M, Ostapenko V, Illiger HJ, Behringer D, Bardy-Bouxin N, Boni J, Kong S, Cincotta M and Moore L: Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23: 5314-5322, 2005. (Pubitemid 46206985)
44. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W and Rugo HS: Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27: 2630-2637, 2009.
45. Soria J-C, Shepherd FA, Douillard J-Y, Wolf J, Giaccone G, Crino L, Cappuzzo F, Sharma S, Gross SH, Dimitrijevic S, Di Scala L, Gardner H, Nogova L and Papadimitrakopoulou V: Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 20: 1674-1681, 2009.
46. Slomovitz BM, Lu KH, Johnston T, Coleman RL, Munsell M, Broaddus RR, Walker C, Ramondetta LM, Burke TW, Gershenson DM and Wolf J: A phase II study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 116: 5415-5419, 2010.
47. Doi T, Muro K, Boku N, Yamada Y, Nishina T, Takiuchi H, Komatsu Y, Hamamoto Y, Ohno N, Fujita Y, Robson M and Ohtsu A: Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 28: 1904-1910, 2010.
48. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, Laurell A, Offner F, Strahs A, Berkenblit A, Hanushevsky O, Clancy J, Hewes B, Moore L and Coiffier B: Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27: 3822-3829, 2009.
49. Witzig TE, Reeder CB, LaPlant BR, Gupta M, Johnston PB, Micallef IN, Porrata LF, Ansell SM, Colgan JP, Jacobsen ED, Ghobrial IM and Habermann TM: A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 25: 341-347, 2011.
50. Atkinson AJ, Colburn WA, DeGruttola VG, DeMets DL, Downing GJ, Hoth DF, Oates JA, Peck CC, Schooley RT, Spilker BA, Woodcock J and Zeger SL: Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 69: 89-95, 2001. (Pubitemid 32225406)
51. Roberts PJ, Stinchcombe TE, Der CJ and Socinski MA: Personalized medicine in non-small cell lung cancer: Is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 28: 4769-4777, 2010.
52. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V and Carroll K: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366: 1527-1537, 2005. (Pubitemid 41540110)
53. Chang A, Parikh P, Thongprasert S, Tan EH, Perng R-P, Ganzon D, Yang C-H, Tsao C-J, Watkins C, Botwood N and Thatcher N: Gefitinib (Iressa) in patients of asian origin with refractory advanced Non-small cell lung cancer: Subset analysis from the ISEL study. J Thorac Oncol 1: 847-855, 2006. (Pubitemid 47181391)
54. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P and Seymour: Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353: 123-132, 2005.
55. Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang J-J, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA and Fukuoka M: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957, 2009.
56. Van Cutsem E, Köhne C-H, Hitre E, Zaluski J, Chang Chien C-R, Makhson A, D'Haens G, Pintér Ts, Lim R, Bodoky Gr, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J and Rougier P: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417, 2009.
57. Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, Papadimitriou CA and Murray S: Assessment of somatic K-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: A systematic review and meta-analysis of studies in advanced non-small cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9: 962-972, 2008.
58. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancey J, Hidalgo M and Walsh DJ: Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study. J Clin Oncol 23: 5294-5304, 2005. (Pubitemid 46206983)
59. Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, Le L, Oza A, Nicklee T, Ho J, Birle D, Pond GR, Arboine D, Dancey J, Aviel-Ronen S, Tsao MS, Hedley D and Siu LL: A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 95: 1148-1154, 2006. (Pubitemid 44660065)
60. Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, Youmans A, Polivy A, Mandato L, McDermott D, Stanbridge E and Atkins M: Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 5: 379-385, 2007. (Pubitemid 47584475)
61. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK and Sawyers CL: Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5: e8, 2008.
62. Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, O'Toole T, Gibbons J, Belldegrun AS and Figlin RA: Prognostic relevance of the mTOR pathway in renal cell carcinoma. Cancer 109: 2257-2267, 2007.
63. Figlin RA, de Souza P, McDermott D, Dutcher JP, Berkenblit A, Thiele A, Krygowski M, Strahs A, Feingold J, Boni J and Hudes G: Analysis of PTEN and HIF-1α and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-α. Cancer 115: 3651-3660, 2009.
64. Iwenofu OH, Lackman RD, Staddon AP, Goodwin DG, Haupt HM and Brooks JSJ: Phospho-S6 ribosomal protein: A potential new predictive sarcoma marker for targeted mTOR therapy. Mod Pathol 21: 231-237, 2007. (Pubitemid 351304283)
65. Tarhini A, Kotsakis A, Gooding W, Shuai Y, Petro D, Friedland D, Belani CP, Dacic S and Argiris A: Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res 16: 5900-5907, 2010.
66. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Cajal SRy, Jones S, Vidal L, Shand N, Macarulla T, Ramos FJ, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane HA, Lebwohl D and Baselga J: Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26: 1603-1610, 2008.
67. Okuno S, Bailey H, Mahoney MR, Adkins D, Maples W, Fitch T, Ettinger D, Erlichman C and Sarkaria JN: A phase II study of temsirolimus (CCI-779) in patients with soft tissue sarcomas. Cancer 117: 3468-3475, 2011.
68. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H and Sawyers CL: Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 98: 10314-10319, 2001. (Pubitemid 32803017)
69. Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R, Tobler S, Heusser C, O'Reilly T, Stolz B, Marti A, Thomas G and Lane HA: Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 64: 252-261, 2004. (Pubitemid 38114106)
70. Ekshyyan O, Mills GM, Lian T, Amirghahari N, Rong X, Lowery-Nordberg M, Abreo F, Veillon DM, Caldito G, Speicher L, Glass J and Nathan CAO: Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma. Head Neck 32: 1619-1628, 2010.
71. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J and Pandolfi PP: Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118: 3065-3074, 2008.
72. Nathan CO, Franklin S, Abreo FW, Nassar R, De Benedetti A and Glass J: Analysis of surgical margins with the molecular marker eIF4E: a prognostic factor in patients with head and neck cancer. J Clin Oncol 17: 2909-2914, 1999. (Pubitemid 29415252)
73. Nathan CO, Amirghahari N, Rong X, Giordano T, Sibley D, Nordberg M, Glass J, Agarwal A and Caldito G: Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer. Cancer Res 67: 2160-2168, 2007. (Pubitemid 46424235)
74. D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH and Gillison ML: Case control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356: 1944-1956, 2007. (Pubitemid 46740304)
75. Baker AF, Dragovich T, Ihle NT, Williams R, Fenoglio-Preiser C and Powis G: Stability of phosphoprotein as a biological marker of tumor signaling. Clin Cancer Res 11: 4338-4340, 2005. (Pubitemid 40825621)
76. Ansell SM, Tang H, Kurtin PJ, Koenig PA, Inwards DJ, Shah K, Ziesmer SC, Feldman AL, Rao R, Gupta M, Erlichman C, Witzig TE.: Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: A multi-center Phase 2 Study. Lancet Oncol 12: 361-368, 2011.
77. Irene M. Ghobrial, Morie Gertz, Betsy LaPlant, John Camoriano, Suzanne Hayman, Martha Lacy, Stacey Chuma, Brianna Harris, Renee Leduc, Meghan Rourke, Stephen M. Ansell, Daniel DeAngelo, Angela Dispenzieri, Leif Bergsagel, Craig Reeder, Kenneth C. Anderson, Paul G. Richardson, Steven P. Treon, Thomas E. Witzig: Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenström macroglobulinemia. J Clin Oncol 10: 1408-1414, 2010.
78. Rizzieri DA, Feldman E, Dipersio JF, Gabrail N, Stock W, Strair R, Rivera VM, Albitar M, Bedrosian CL, Giles FJ.: A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 14: 2756-2562, 2008.
79. Okuno S, Bailey H, Mahoney MR, Adkins D, Maples W, Fitch T, Ettinger D, Erlichman C, Sarkaria JN.: A Phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: A study of the Mayo phase 2 consortium (P2C). Cancer 117: 3468-3475, 2011.